title: MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma.
abstract: Indolent primary cutaneous B-cell lymphoma is a group of malignant lymphomas comprising marginal zone B-cell lymphoma and centrofollicular B-cell lymphoma. Relapse rate of these tumors is close to 40%, and identifying those patients who are likely to progress remains a challenge. The aim of this study was to characterize the microRNA (miRNA) expression profile of a series of primary cutaneous B-cell lymphomas and correlate with histological and clinical findings. We studied a series of 68 patients with primary cutaneous B-cell lymphomas (30 cutaneous marginal-zone B-cell lymphomas and 38 primary cutaneous centrofollicular lymphomas). A set of 11 miRNAs associated with the differentiation stage of B cells was quantified by real-time PCR, using RNA extracted from formalin-fixed, paraffin-embedded tissue diagnostic samples. Relevant clinical variables were retrieved in a subset of 57 patients (28 cutaneous marginal zone B-cell lymphomas and 29 primary cutaneous centrofollicular lymphomas). miR-150 was upregulated in cutaneous marginal zone B-cell lymphomas relative to primary cutaneous centrofollicular lymphoma samples (false discovery rate <0.05). miR-155 and miR-150 expression levels were associated with progression-free survival in a univariate Cox regression analysis (P<0.1). After stratification by histological subtype, low-expression levels of miR-155 and miR-150 were both associated with shorter progression-free survival only in primary cutaneous marginal zone B-cell lymphomas cases (log-rank test, P<0.05). In summary, miRNA expression analysis can be used as a tool for diagnosis and outcome prognosis in indolent primary cutaneous B-cell lymphoma.
authors.affiliation: Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain.
authors.forename: Veronica
authors.initials: V
authors.lastname: Monsálvez
authors.forename: Santiago
authors.initials: S
authors.lastname: Montes-Moreno
authors.forename: María J
authors.initials: MJ
authors.lastname: Artiga
authors.forename: Maria E
authors.initials: ME
authors.lastname: Rodríguez
authors.forename: Beatriz
authors.initials: B
authors.lastname: Sanchez-Espiridion
authors.forename: Beatriz S
authors.initials: BS
authors.lastname: Espiridión
authors.forename: Maria
authors.initials: M
authors.lastname: Lozano
authors.forename: Ricardo
authors.initials: R
authors.lastname: Fernández-de-Misa
authors.forename: Jose L
authors.initials: JL
authors.lastname: Rodríguez-Peralto
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Piris
authors.forename: Pablo L
authors.initials: PL
authors.lastname: Ortíz-Romero
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D016393:Lymphoma, B-Cell / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D008297:Male; D035683:MicroRNAs; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D015996:Survival Rate
chemical_list: D035683:MicroRNAs